Dentsply Sirona Launches Smart View - Detect, World’s First FDA-Cleared AI-enabled diagnostic aid for detecting teeth with Periapical Radiolucencies in CBCTs

Rhea-AI Summary

Dentsply Sirona (NASDAQ:XRAY) launched Smart View - Detect, the first FDA-cleared AI-enabled diagnostic aid for detecting teeth with periapical radiolucencies (PARLs) in CBCT scans, also CE approved in Europe. The company reports an internal multi-reader study showing ~46% relative increase in tooth-level PARL detection sensitivity versus unaided review. Available via DS Core for compatible Orthophos S, Orthophos SL, and Axeos systems; supports 5×5 to 17×11 fields of view. The feature is accessible for new and historical CBCT scans and will be available May 12, 2026, requiring a DS Core Standard or Advanced subscription.

AI-generated analysis. Not financial advice.

Positive

• FDA clearance and CE approval for AI-enabled PARL detection
• Internal study: ~46% relative increase in tooth-level PARL sensitivity
• Available May 12, 2026 for new and existing compatible CBCT systems
• Works with 5×5 to 17×11 fields of view and historical scans

Negative

• Requires DS Core Standard or Advanced subscription
• Benefit based on an internal multi-reader study, not an independent external trial
• Does not provide a diagnosis; intended only as a review aid
• Limited to compatible Dentsply Sirona CBCT systems (Orthophos S, SL, Axeos)

News Market Reaction – XRAY

-5.17%

3 alerts

-5.17% News Effect

-$124M Valuation Impact

$2.28B Market Cap

0.0x Rel. Volume

On the day this news was published, XRAY declined 5.17%, reflecting a notable negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $124M from the company's valuation, bringing the market cap to $2.28B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

PARL prevalence: approximately 52% of adults Detection sensitivity gain: approximately 46% relative increase Fields of view supported: 5×5 to 17×11 +1 more

4 metrics

PARL prevalence approximately 52% of adults Published research on periapical radiolucencies

Detection sensitivity gain approximately 46% relative increase Internal multi-reader, multi-case CBCT study with Smart View - Detect

Fields of view supported 5×5 to 17×11 Range of CBCT scan fields compatible with Smart View - Detect

Availability date May 12, 2026 Smart View - Detect launch in U.S. and Europe

Market Reality Check

Price: $11.00 Vol: Volume 3570883 vs 20-day ...

normal vol

$11.00 Last Close

Volume Volume 3570883 vs 20-day average 3192356 ahead of the AI product launch news. normal

Technical Price 11.81 is trading below the 200-day MA of 12.62, and about one-fifth above the 52-week low of 9.85.

Peers on Argus

Peers show mixed moves: NVST and LMAT are up, while ICUI and MMSI are down. With...

Peers show mixed moves: NVST and LMAT are up, while ICUI and MMSI are down. With XRAY modestly positive and no peers in the momentum scanner, the move appears company-specific rather than a broad dental/med-tech rotation.

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 30	Product launch	Positive	+2.4%	U.S. launch of Surity Male External Catheter expanding continence portfolio.
Apr 22	Earnings call setup	Neutral	-2.2%	Announcement of timing and access details for Q1 2026 earnings call.
Mar 09	Regulatory clearance	Positive	+0.5%	FDA clearance and clinical validation of first dental-dedicated MRI system.
Mar 03	Conference participation	Neutral	+1.1%	Plan to present at Leerink Partners Global Healthcare Conference 2026.
Feb 26	Earnings and outlook	Neutral	+15.5%	Q4 and FY 2025 results plus 2026 sales and EPS guidance with restructuring.

Pattern Detected

Recent news, especially product and technology launches, has generally seen positive price alignment, while routine event announcements have sometimes diverged.

Recent Company History

Over the last six months, XRAY’s news flow has included product launches, technology milestones, earnings, and investor events. The FDA-cleared dental MRI collaboration with Siemens Healthineers and the Wellspect Surity continence product expansion both coincided with mild positive moves. The Q4 2025 earnings and 2026 outlook release saw a stronger positive reaction of 15.5%. Conference-related announcements produced smaller, mixed reactions. Today’s AI-enabled CBCT diagnostic aid launch continues the theme of imaging and technology innovation within the portfolio.

Market Pulse Summary

The stock moved -5.2% in the session following this news. A negative reaction despite this AI-enable...

Analysis

The stock moved -5.2% in the session following this news. A negative reaction despite this AI-enabled imaging launch would contrast with generally constructive responses to prior technology and product announcements, where moves up to 15.5% followed major updates. XRAY’s price remains below its 200-day MA of 12.62, and recent filings include proxy items such as incentive plan share increases, which can influence sentiment. Past divergence around routine events suggests that broader macro or positioning factors can outweigh single-product news.

Key Terms

periapical radiolucencies, cbct, endodontic, fda cleared, +1 more

5 terms

periapical radiolucencies medical

"detecting teeth with periapical radiolucencies (PARLs) and supports efficient CBCT review"

Periapical radiolucencies are dark spots seen on dental X-rays around the tip of a tooth’s root that usually indicate loss of bone from infection, inflammation, or long‑standing dental disease. For investors, these findings are signals that can affect demand for dental treatments, diagnostic products, or prescription drugs and may influence regulatory reviews, clinical trial outcomes, liability exposure, and revenue projections—think of them as warning lights on a car dashboard pointing to underlying problems that may require costly fixes.

cbct medical

"teeth with Periapical Radiolucencies in CBCTs"

Cone beam computed tomography (CBCT) is a type of 3D X‑ray scan that creates detailed, three‑dimensional images of teeth, jaws and facial bones by rotating a cone‑shaped X‑ray beam around the head. For investors, CBCT matters because it drives demand for specialized imaging equipment, software and clinics; changes in adoption, reimbursement or regulatory approval can directly affect revenues and margins in dental and medical device businesses. Think of it as upgrading from a flat photo to a full 3D model that clinicians use to plan treatment more precisely.

endodontic medical

"PARLs often require endodontic treatment, underscoring the importance of accurate detection"

Relating to endodontics, the dental specialty that diagnoses and treats problems inside the tooth—especially the pulp and root canals—often described as the tooth’s internal plumbing for pain relief and tooth preservation. Investors track endodontic products and services because they drive steady procedure volumes and equipment sales, are affected by regulatory approvals and insurance reimbursement, and can indicate demand trends in dental care and medical-device markets.

fda cleared regulatory

"the world’s first FDA Cleared AI-enabled diagnostic aid for detecting teeth with PARL"

FDA cleared means the U.S. Food and Drug Administration reviewed a medical device and agreed it is similar enough to an already allowed product to be marketed in the United States. Think of it like a new car model using largely the same, proven parts as an earlier model — the regulator gives a green light for sales but does not imply the more extensive testing required for full approval. For investors, clearance signals regulatory access to the U.S. market and typically lowers commercialization risk compared with no clearance.

ce approved regulatory

"AI-enabled diagnostic aid for detecting teeth with PARL in CBCTs, also CE approved in Europe"

CE approved means a product has met the European Union’s safety, health and environmental rules and bears the CE mark, which allows it to be sold across the EU/EEA. For investors, this is like a product getting a passport or safety sticker: it signals the company cleared a key regulatory hurdle that can open large markets, reduce legal risk, and affect potential sales and valuation.

AI-generated analysis. Not financial advice.

Smart View - Detect is associated with a ~46% relative increase¹ in detection of teeth with periapical radiolucencies (PARLs) and supports efficient CBCT review and clearer patient communication. Available through DS Core², Smart View - Detect is compatible with both newly installed and existing Dentsply Sirona CBCT systems.

CHARLOTTE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, today announced the launch of Smart View - Detect, the world’s first FDA Cleared AI-enabled diagnostic aid for detecting teeth with PARL in CBCTs, also CE approved in Europe. The AI-assisted support feature is designed to help clinicians review CBCT scans more efficiently and clearly when evaluating potential periapical radiolucencies (PARLs).

Periapical radiolucencies (PARLs) are a common clinical finding, with published research³ showing that approximately 52% of adults have at least one tooth affected. PARLs often require endodontic treatment, underscoring the importance of accurate detection and review.

While CBCT imaging is widely recognized for its diagnostic value, reviewing the depth of information contained in full 3D volumes can feel intimidating in everyday practice. Smart View – Detect is designed to help reduce the risk of overlooked findings by visually highlighting specific areas within CBCT scans where potential PARLs may be present. This supports efficient review and helps patients more easily understand what their dentist is seeing.

In an internal multi-reader, multi-case clinical study comparing AI-assisted versus unaided CBCT review, clinicians using Smart View - Detect increased tooth-level PARL detection sensitivity by approximately 46% relative to unaided review, without meaningfully increasing false positives.

Supporting Clearer Patient Conversations

Beyond review support, Smart View - Detect also enhances communication with patients by visually highlighting areas of interest directly within CBCT scans. This clarity helps patients easily understand what their dentist is seeing, supporting informed, confident, and productive treatment discussions. While Smart View - Detect does not provide a diagnosis, its visual presentation can help strengthen understanding, engagement, and trust during consultations.

“Smart View - Detect is designed to support dentists at two important moments—when reviewing complex CBCT data and when explaining findings to patients,” said Wolf-Dieter Perlitz, Senior Director DS Core at Dentsply Sirona. “By bringing a first of its kind AI-based diagnosis support into DS Core, we continue to advance the value of Connected Dentistry, helping clinicians feel confident in their evaluations, work more efficiently, and communicate more clearly with patients.”

DS Core: Reducing Digital Complexity to Support Efficient, High-Quality Care

Smart View - Detect is available through DS Core, Dentsply Sirona’s cloud-based platform, allowing AI-supported insights to be accessed directly as part of its imaging workflow. Through DS Core, Dentsply Sirona is working to reduce the operational and clinical complexity associated with digital dentistry by continuously evolving the platform, expanding its capabilities, and applying insights from real-world use to support more efficient workflows and informed clinical decision making.

Availability, Integration, and System Compatibility

Smart View - Detect is available for both newly installed and existing compatible Dentsply Sirona CBCT systems, including Orthophos S, Orthophos SL, and Axeos. Customers with a DS Core account can benefit from Smart View - Detect as an added capability within their existing setup, without the need to purchase new imaging equipment.

The feature supports all fields of view from 5×5 to 17×11 and works with both newly acquired and historical CBCT scans transferred from Sidexis 4 into DS Core.

Smart View - Detect will be available starting May 12, 2026, in the United States and Europe, and requires a DS Core Standard or Advanced subscription.

For more information, visit: DS Core - Diagnose Features: Smart View – Detect - YouTube

Registered brands, trade names and logos are used. Even in particular cases, when they appear without a TM or ®, all corresponding legal rules and provisions apply. All rights are retained by Dentsply Sirona. Clinicians may have been compensated for use of their experiences and testimonials.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information:

Dentsply Sirona Press Contact:
Marion Par-Weixlberger
Vice President, Corporate Communications, Public Relations & Brand
Publicrelations@dentsplysirona.com | www.dentsplysirona.com

¹ Based on results from an internal multi-reader, multi-case clinical study evaluating AI-assisted versus unassisted CBCT readings for periapical radiolucency detection.
² Requires DS Core Standard tier or above
³ https://pubmed.ncbi.nlm.nih.gov/33378579/

FAQ

What is Smart View - Detect and when will XRAY make it available?

Smart View - Detect is an FDA-cleared AI aid for PARL detection in CBCTs, available May 12, 2026. According to Dentsply Sirona, it will be distributed via DS Core and support compatible Orthophos S, Orthophos SL, and Axeos systems for new and historical scans.

How much did Smart View - Detect improve PARL detection in Dentsply Sirona's study?

Clinicians using Smart View - Detect showed about a 46% relative increase in tooth-level PARL sensitivity. According to Dentsply Sirona, this result came from an internal multi-reader, multi-case clinical study comparing AI-assisted versus unaided CBCT review.

Does Smart View - Detect replace a dental diagnosis for XRAY patients?

No. Smart View - Detect does not provide a diagnosis and is intended as a visual review aid. According to Dentsply Sirona, it highlights potential PARLs to support clinician review and patient communication but clinicians remain responsible for final diagnosis and treatment decisions.

Which Dentsply Sirona CBCT systems and fields of view support Smart View - Detect?

Smart View - Detect supports Orthophos S, Orthophos SL, and Axeos systems and fields of view from 5×5 to 17×11. According to Dentsply Sirona, it works with both newly acquired and transferred historical CBCT scans via DS Core.

What do clinics need to use Smart View - Detect for XRAY patients?

Clinics need a DS Core account with a Standard or Advanced subscription to access Smart View - Detect. According to Dentsply Sirona, no new imaging hardware purchase is required for compatible existing CBCT systems, but subscription access is mandatory.